- Home
- CTSO vs UNCY Comparison
CTSO vs UNCY Comparison
Compare CTSO & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- UNCY
- Stock Information
- Founded
- CTSO 1997
- UNCY 2016
- Country
- CTSO United States
- UNCY United States
- Employees
- CTSO N/A
- UNCY N/A
- Industry
- CTSO Medical/Dental Instruments
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- CTSO Health Care
- UNCY Health Care
- Exchange
- CTSO Nasdaq
- UNCY Nasdaq
- Market Cap
- CTSO 68.2M
- UNCY 71.8M
- IPO Year
- CTSO N/A
- UNCY 2021
- Fundamental
- Price
- CTSO $0.87
- UNCY $0.55
- Analyst Decision
- CTSO Strong Buy
- UNCY Strong Buy
- Analyst Count
- CTSO 3
- UNCY 3
- Target Price
- CTSO $4.67
- UNCY $5.50
- AVG Volume (30 Days)
- CTSO 138.6K
- UNCY 511.5K
- Earning Date
- CTSO 05-14-2025
- UNCY 05-16-2025
- Dividend Yield
- CTSO N/A
- UNCY N/A
- EPS Growth
- CTSO N/A
- UNCY N/A
- EPS
- CTSO N/A
- UNCY N/A
- Revenue
- CTSO $35,594,520.00
- UNCY N/A
- Revenue This Year
- CTSO $18.72
- UNCY N/A
- Revenue Next Year
- CTSO $19.75
- UNCY $1,502.84
- P/E Ratio
- CTSO N/A
- UNCY N/A
- Revenue Growth
- CTSO 14.51
- UNCY N/A
- 52 Week Low
- CTSO $0.70
- UNCY $0.20
- 52 Week High
- CTSO $1.61
- UNCY $1.16
- Technical
- Relative Strength Index (RSI)
- CTSO 34.05
- UNCY 39.05
- Support Level
- CTSO $0.87
- UNCY $0.59
- Resistance Level
- CTSO $1.16
- UNCY $0.66
- Average True Range (ATR)
- CTSO 0.06
- UNCY 0.04
- MACD
- CTSO -0.02
- UNCY -0.01
- Stochastic Oscillator
- CTSO 0.34
- UNCY 4.00
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.